FEMSA ANNOUNCES THE TOTAL CONSIDERATION FOR ITS PREVIOUSLY ANNOUNCED TENDER OFFER
MONTERREY, Mexico, June 17, 2024 /PRNewswire/ — FOMENTO ECONÓMICO MEXICANO, S.A.B. DE C.V. (“FEMSA“) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) today... Read more.
Ispire Technology Inc. Announces Participation in the Next Generation Nicotine Delivery USA 2024 Conference
LOS ANGELES, June 17, 2024 /PRNewswire/ — Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a leader in the development... Read more.
Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics
SAN DIEGO, June 17, 2024 /PRNewswire/ — Primrose Bio, Inc. (“Primrose,” the “Company”), a company focused on developing and licensing... Read more.
Cantor hires Deepak Mathivanan as Senior Internet Research Analyst
NEW YORK, June 17, 2024 /PRNewswire/ — Cantor, a premier global financial institution, today announced that Deepak Mathivanan will join the firm as a Managing... Read more.
Vosyn Unveils AI Advancements at Collision Conference, Announces $8MM Round
TORONTO, June 17, 2024 /PRNewswire/ – Vosyn, the AI startup revolutionizing real-time multilingual content experiences, is announcing its debut at Collision... Read more.
LendingClub Exceeds $3 Billion in Loans Sold Through Its Structured Certificates Program
SAN FRANCISCO, June 17, 2024 /PRNewswire/ — LendingClub Corporation (NYSE: LC), the parent company of LendingClub Bank (“LendingClub”), America’s... Read more.
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
CARLSBAD, Calif., June 17, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat... Read more.
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, June 17, 2024 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... Read more.
First-in-Disease Use of Kyverna Therapeutics’ KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
Patient received KYV-101, a fully human anti-CD19 CAR T-cell product candidate, as part of a named-patient treatment option after failure to respond to conventional... Read more.
Datadog Launches New App Builder for DevSecOps Teams
Customers like PayByPhone and NationBuilder use Datadog App Builder to improve incident response, visualize data and streamline internal processes NEW YORK, June... Read more.